Vanda Pharmaceuticals (VNDA) Interest Coverage Ratio: History & Chart

Vanda Pharmaceuticals Inc.(VNDA)

Biotechnology · Washington, DC

$4.48-0.11 (-2.29%)

Delayed quote: Oct 6, 2026, 3:25 PM EDT

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.

Washington, DC

533 employees

www.vandapharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mihael H. Polymeropoulos

View full financials

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Vanda Pharmaceuticals Inc. (VNDA)	$269.11M	N/A	N/A	N/A	N/A
TriSalus Life Sciences, Inc. (TLSI)vs ›	$267.23M	-4.86x	N/A	N/A	N/A
SAB Biotherapeutics, Inc. (SABS)vs ›	$270.24M	-203.41x	43.82x	43.82x	43.82x
Inhibikase Therapeutics, Inc. (IKT)vs ›	$265.78M	N/A	N/A	N/A	N/A
Fate Therapeutics, Inc. (FATE)vs ›	$268.67M	N/A	N/A	N/A	N/A
Scribe Therapeutics Inc. (SCTX)vs ›	$265.14M	N/A	N/A	N/A	N/A
Rocket Pharmaceuticals, Inc. (RCKT)vs ›	$270.25M	-120.84x	N/A	N/A	N/A
Palisade Bio, Inc. (PALI)vs ›	$263.84M	-1805.60x	N/A	N/A	N/A
Treace Medical Concepts, Inc. (TMCI)vs ›	$264.36M	-10.18x	0.19x	0.19x	0.19x
Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›	$260.30M	-530.37x	N/A	N/A	N/A

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Vanda Pharmaceuticals Inc. (VNDA)

$269.11M

N/A

TriSalus Life Sciences, Inc. (TLSI)vs ›

$267.23M

-4.86x

N/A

SAB Biotherapeutics, Inc. (SABS)vs ›